Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Forecast Insight - Migraine - Generic incursion inhibits market growth (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 17/12/2008
- Report Title: Forecast Insight - Migraine - Generic incursion inhibits market growth
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 80
Introduction
Led by the seven triptan brands and Topamax's (topiramate; Johnson & Johnson) continued uptake, seven major market migraine revenues grew strongly at an annual rate of 12.6% to total $4.1 billion in 2007.
Scope
*This report gives a strategic analysis of the likely impact that recent events will have on the future migraine market
*Includes migraine-specific sales forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2017
*Provides a global market snapshot by including migraine-specific sales analysis for leading brands outside the seven major markets
*Key conclusions are supported by key opinion leader comment
Highlights
A 3-month direct-to-consumer (DTC) advertisement review process delayed print and televised branded marketing campaigns for Treximet until late September 2008. As a result, early awareness of Treximet was crucially limited and so Datamonitor has marginally downgraded its forecast.
With continued key opinion leaders enthusiasm and promising Phase III comparator trial results, demonstrating a similar efficacy profile to AstraZeneca's Zomig (zolmitriptan 5mg) and a potentially improved side-effect profile, Datamonitor has upgraded its migraine-specific sales forecast for Merck & Co's telcagepant.
Datamonitor has considerably upgraded its migraine-specific sales forecast of Botox (botulinum toxin Type-A, Allergan). This is due to a greater than previously expected dosing regimen and Ipsen no longer assumed to be seeking a migraine label for its botulinum toxin brand Dysport, reducing future market competition.
Reasons to Purchase
*Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2008 to 2017
*Quantify the current size of the seven major markets and the trends in the rest of the world
*Assess the impact of events, such as patent expiries and new product launches, on the migraine-specific sales of key brand name products
Led by the seven triptan brands and Topamax's (topiramate; Johnson & Johnson) continued uptake, seven major market migraine revenues grew strongly at an annual rate of 12.6% to total $4.1 billion in 2007.
Scope
*This report gives a strategic analysis of the likely impact that recent events will have on the future migraine market
*Includes migraine-specific sales forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2017
*Provides a global market snapshot by including migraine-specific sales analysis for leading brands outside the seven major markets
*Key conclusions are supported by key opinion leader comment
Highlights
A 3-month direct-to-consumer (DTC) advertisement review process delayed print and televised branded marketing campaigns for Treximet until late September 2008. As a result, early awareness of Treximet was crucially limited and so Datamonitor has marginally downgraded its forecast.
With continued key opinion leaders enthusiasm and promising Phase III comparator trial results, demonstrating a similar efficacy profile to AstraZeneca's Zomig (zolmitriptan 5mg) and a potentially improved side-effect profile, Datamonitor has upgraded its migraine-specific sales forecast for Merck & Co's telcagepant.
Datamonitor has considerably upgraded its migraine-specific sales forecast of Botox (botulinum toxin Type-A, Allergan). This is due to a greater than previously expected dosing regimen and Ipsen no longer assumed to be seeking a migraine label for its botulinum toxin brand Dysport, reducing future market competition.
Reasons to Purchase
*Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2008 to 2017
*Quantify the current size of the seven major markets and the trends in the rest of the world
*Assess the impact of events, such as patent expiries and new product launches, on the migraine-specific sales of key brand name products
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
